Multimodal information fusion for the diagnosis of diabetic retinopathy

Diabetes is a chronic disease characterized by excess sugar in the blood and affects 422 million people worldwide, including 3.3 million in France. One of the frequent complications of diabetes is diabetic retinopathy (DR): it is the leading cause of blindness in the working population of developed countries. As a result, ophthalmology is on the verge of a revolution in screening, diagnosing, and managing of pathologies. This upheaval is led by the arrival of technologies based on artificial intelligence. The "Evaluation intelligente de la r\'etinopathie diab\'etique" (EviRed) project uses artificial intelligence to answer a medical need: replacing the current classification of diabetic retinopathy which is mainly based on outdated fundus photography and providing an insufficient prediction precision. EviRed exploits modern fundus imaging devices and artificial intelligence to properly integrate the vast amount of data they provide with other available medical data of the patient. The goal is to improve diagnosis and prediction and help ophthalmologists to make better decisions during diabetic retinopathy follow-up. In this study, we investigate the fusion of different modalities acquired simultaneously with a PLEXElite 9000 (Carl Zeiss Meditec Inc. Dublin, California, USA), namely 3-D structural optical coherence tomography (OCT), 3-D OCT angiography (OCTA) and 2-D Line Scanning Ophthalmoscope (LSO), for the automatic detection of proliferative DR.